

EFFICACY OF SELF-ADMINISTRATION OF A PERSONAL MECHANICAL EYELID DEVICE FOR THE TREATMENT OF DRY EYE DISEASE, BLEPHARITIS, AND MEIBOMIAN GLAND DISEASE

David Schanzlin MD¹, John Olkowski MD², John Coble OD³, Wendy Gross OD¹, Michael Dash OD²

¹Gordon-Schanzlin New Vision Institute, San Diego, CA

²EyeSight Hawaii Vision Institute, Honolulu, HI

³Eyecare of Greenville, Greenville, TX

Corresponding Author: jolkowski1@gmail.com

Submitted: November 3, 2019. Accepted: December 17, 2019. Published: January 21, 2020.

ABSTRACT

Purpose

A prospective study to evaluate the safety and efficacy of a novel mechanical eyelid device (NuLids™ by NuSight Medical, LLC, Rancho Santa Fe, CA) used at home for the treatment of dry eye disease (DED), blepharitis (anterior and posterior) and meibomian gland disease (MGD).

Methods

Seventy-four (74) eyes of thirty-seven (37) patients were self-treated with the NuLids™ device at home. Inclusion criteria included blepharitis, MGD and/or DED. After an initial training session, each eyelid was treated for 15 seconds (total of 1 minute per treatment session per day). The following tests were collected before the first treatment and after the final treatment: OSDI survey, BCVA, Tear Osmolarity Test (Tear Lab), Tear Break Up Time (TBUT), Meibomian Gland Score (MGS), Meibomian Glands Yielding Liquid Secretions (MGYLS), Sicca Ocular Staining Score. Satisfaction with treatment survey was taken after treatment.

Results

All measured parameters had a statistically significant improvement. Symptoms improved based on an average decrease in OSDI score from 54.2 ± 19.5 (mean \pm SD) to 26.7 ± 18.4 ($P < 0.001$). Tear osmolarity improved from 315 ± 15.7 to 306 ± 13.9 ($P = 0.002$). TBUT was noted to improve from pre-treatment of 4.8 ± 1.7 seconds to post-treatment of 7.9 ± 4.1 seconds ($P < 0.001$). MGS improved from 8.9 ± 5.1 to 7.0 ± 5.9 ($P = 0.01$). MGYLS improved from 8.7 ± 6.2 to 15.8 ± 6.9 ($P = 0.002$). Sicca Ocular Staining Score improved from 2.7 ± 2.1 to 1.4 ± 1.5 ($P = 0.002$).

There were no adverse events. No corneal or conjunctival trauma. No patients dropped out of the trial due to discomfort. 91% of participants agreed or strongly agreed that the device was easy and convenient to use. Of those previously using manual lid scrubs, 82% felt the NuLids device was easier and more comfortable to use. 89% described little or no discomfort. 95% were satisfied or very satisfied with the overall treatment.

Conclusions

A mechanical device was safely used by patients at home for 1 minute daily for 30 days to treat DED, blepharitis, and MGD. There was a statistically significant improvement in signs and symptoms of DED as shown by improved OSDI, tear osmolarity, TBUT, MGS, MGYLS, and Ocular Staining Score. High patient satisfaction along with the low risk of adverse events supports the use of this device as a valid tool to treat DED, blepharitis, and MGD.

Key words: *Dry eye disease, blepharitis, Meibomian gland disease, mechanical eyelid device*

Dry eye disease (DED), blepharitis and Meibomian gland disease (MGD) are some of the most common disorders encountered in an eye care practice. It is estimated that over 16 million U.S. adults have diagnosed DED.¹ MGD is the most common etiology of DED, accounting for 86% of all dry eye patients.² MGD results in decreased and poor quality oil production, which leads to evaporative DED.³ The lipids produced by the Meibomian glands are essential to maintain tear film stability, reduce evaporation and maintain a healthy ocular surface with improved visual acuity.⁴

Eyelid hygiene is one of the cornerstones of MGD treatment.⁵ The principal goal of treatment of MGD is to improve the quantity and quality of oil secretion from the glands which then decreases dry eye symptoms. Early treatment is very important⁶ as this can prevent long-term dry eye disease. There is a relatively high level of meibomian gland disease in the pediatric population.⁸ Therefore, early detection and patient education as to the long-term ramification of DED is paramount. Meibomian gland disease is underdiagnosed and there is an unmet need for additional treatment modalities besides warm compresses and manual eyelid scrubs. Recently, office-based lid treatments have emerged, but these are both costly and inconvenient for the patient. A therapy that is less expensive and not requiring office visits should increase patient compliance. This study evaluates a novel new device for personal self-administrated treatment of Meibomian gland disease, blepharitis, and dry eye disease.

MATERIALS AND METHOD

This was a multicenter, prospective study to evaluate the safety and efficacy of a mechanical device, NuLids™ (NuSight Medical, Ranch Santa Fe, CA) for at-home treatment of DED, blepharitis, and MGD.

Patients were recruited from the private practices of the authors of this paper. Informed consent was obtained by the institutional review board (WIRB) committee approval. Inclusion criteria were age 18 years and above and the ability to cooperate for the study. Also, patients were required to have an OSDI score greater than 25. Visual acuity of 20/40 or better was needed in both eyes. Subjects were also required to have a tear osmolarity greater than 308 mOsm/L in at least one eye using the TearLab Osmolarity System (TearLab, San Diego, CA) and a tear break up time (TBUT) of seven seconds or less in one eye.

This study was performed in compliance with the ethical principles of the declaration of Helsinki and Good Clinical Practice and was approved by Western Institutional Review Board (Puyallup, WA).

Exclusion criteria included any eye surgery in the last three months, history of previous herpetic eye disease or unwillingness to use a mechanical device near their eye. The patient's clinical chart review was also performed to collect relevant information regarding the patient's ocular history (including surgery, medication use, and ocular or systemic disease). The patients were maintained on all existing therapies.

Each patient was asked to complete an Ocular Surface Disease Index (OSDI) questionnaire to assess the degree of dry eye symptoms. Also, patients had visual acuity testing. Tear osmolarity was performed before examining the patient and before any drops were applied. Subjects were instructed not to use any drops in the eye on the day of examination. Slit-lamp examination included Tear Breakup Time (TBUT) after the instillation of sodium fluorescein solution. Also, a Meibomian gland score was assessed using the central five (5) Meibomian glands of the lower lid. Scores range from 0 (clear; normal) to 3 (inspissated;

like toothpaste). When assessing the expression of a fixed number of glands, the sum of scores is recorded for each expressed gland to achieve a composite score. Thus, to grade the central five (5) glands of the lower eyelid, the scores range from 0 – 15 for each lower eyelid.

Meibomian glands yielding liquid secretions (MGYLS) were assessed for the nasal and central regions of the upper and lower eyelids using a standardized pressure device (Meibomian Gland Analyzer, Tear Science, Johnson and Johnson). A score of 0-16 was recorded for each eyelid, counting the number of glands from which fluid meibum may be expressed, with a total score of 0-32 per eye. Ocular surface staining was evaluated using fluorescein and lissamine green using the Sicca Ocular Staining Score (SOSS).

After in-office training, the patients were asked to use the NuLids™ device (NuSight Medical, Rancho Santa Fe, CA) at home daily treating each eyelid margin for 15 seconds daily. The NuLids™ device is a handheld electromechanical device that uses a single-use disposable SoftTip with exposed silicone bristles. The SoftTip oscillates to facilitate the cleaning of bacteria, mites and desiccated skin from the eyelid margin as well as decapping or opening Meibomian gland orifices. Massaging or sonic stimulation of the lid margin may also act to mechanically break up stagnant meibum in the glands and improving circulation. Subjects were instructed to pull and evert the lower lids away from the eye for lower lid treatment and to close lids and evert upper lid for upper eyelid treatment. Hypochlorous Acid Gel 0.2% (Ocusoft *Hypochlor*™) was used to apply on the Soft Tip head. At the end of 30 days, the patients returned for an evaluation where pretreatment testing was repeated, and an exit survey administered.

RESULTS

A total of 74 eyes of 37 participants were evaluated. The mean age of subjects was 54.9 ± 13.3 years. 30 patients were female and 7 males.

The OSDI has a possible total score ranging from 0 to 100 (severe dry eye). All subjects completed the OSDI questionnaire before and after a 30-day treatment. The average entrance OSDI score was 54.2 ± 19.5 . After 30 days of treatment, the average OSDI score decreased to 26.7 ± 18.4 ($P < 0.001$). 92% of the patients showed an approved OSDI. Tear osmolarity improved from 315 ± 15.7 to 306 ± 13.9 ($P = 0.002$). Tear breakup time improved from the pretreatment of 4.8 ± 1.7 seconds to post-treatment of 7.9 ± 4.1 seconds ($P < 0.001$). Meibomian glands score (MGS) improved from 8.9 ± 5.1 to 7.0 ± 5.9 ($P = 0.01$). Meibomian glands yielding liquid secretion (MGYLS) improved from 8.7 ± 6.2 to 15.8 ± 6.9 ($P = 0.002$). Sicca ocular staining score (SOSS) improved from 2.7 ± 2.1 to 1.4 ± 1.5 ($P = 0.002$).

No adverse events reported. There was no trauma to the cornea or bulbar conjunctiva. The patient satisfaction survey revealed that 91% of patients agree or strongly agree that the device was easy and convenient to use. 89% noted little or no discomfort. Of those previously using manual lid scrubs, 82% felt the NuLids device was easier and more comfortable to use. 91% were comfortable using the NuLids device within one week. A total of 95% of patients were satisfied or very satisfied with the overall treatment.

DISCUSSION

Since the original discussion by Wolff in 1946,⁸ most maintain that the main role of the tear film lipid

TABLE 1 Results of the OSDI Questionnaire

	Pre-Treatment	Post-Treatment	P-value
OSDI	54.2 ± 19.5	26.7 ± 18.4	$P < 0.001$
TOT (mOsm/L)	315 ± 15.7	306 ± 13.9	$P = 0.002$
TBUT (seconds)	4.8 ± 1.7	7.9 ± 4.1	$P < 0.001$
MGS	8.9 ± 5.1	7.0 ± 5.9	$P = 0.01$
MGYLS	8.7 ± 6.2	15.8 ± 6.9	$P = 0.002$
SOSS	2.7 ± 2.1	1.4 ± 1.5	$P = 0.002$

layer is to decrease the evaporation of the tears from the eye.⁹ Tear film instability, generally relates to the functionality of the tear film. The DEWS report describes that tear film instability is evidenced by early tear film break-up time, as well as tear hyperosmolarity, representing the two of the main mechanisms of DED.¹⁰ Also, in later stages, ocular staining can be seen.

The normal tear film lipid layer reduces evaporation by about 90–95%.¹¹ Normally, clear oil (meibum) can be expressed from the meibomian orifices by pressing on the glands through the lids.¹² Simple obstructive Meibomian gland disease is the most common form of MGD.¹³ In these cases, pressure on the eyelid margin will not yield oil from the glands.

Lid hygiene has been shown to produce decreased dry eye symptoms¹⁴ and is commonly recommended as a first-line treatment for blepharitis and MGD. However, many patients with DED report no dry eye symptoms when evaluated for routine eye care. In one study, only 57% of patients with DED reported dry eye symptoms.¹⁵ Thus, it is imperative to evaluate the eyelids and Meibomian glands during routine eye exams even when no dry eye symptoms are described. Evaluating Meibomian gland function has been shown to improve the ability to predict DED.¹⁶ If Meibomian glands disease is diagnosed early and treated early, even without symptoms of dry eye, then DED may be avoided. Continued patient education about eyelid health can play an important role in long-term total ocular health.

The NuLids™ device resulted in improvements both in the signs and symptoms of DED. The hypothesized mechanisms of action for this treatment include:

- Cleaning bacteria and desiccated skin from the eyelid margin
- Decapping or opening Meibomian gland orifices
- Massaging or sonic stimulation of lid margin thus mechanically breaking up stagnant meibum in the glands and improving circulation.

As this device is used more commonly in general practice a better understanding will be generated as to the possibility of more optimal time and frequency of use for this device. Many patients have been using this device for over a year so that more information regarding long term outcomes should become more accessible.

In conclusion, self-administration of a personal mechanical eyelid device (NuLids™) to treat DED, blepharitis, and MGD improved both signs and symptoms of dry eyes after treatment of 1 minute per day for 30 days. Patients safely used this mechanical device at home daily for 30 days to treat DED, blepharitis (anterior and posterior) and MGD and required only minimal initial instruction. There was a statistically significant improvement in OSDI, tear osmolarity, TBUT, MGS, MGYLS, and Ocular Staining Score. This data along with a high patient satisfaction along and a low risk of adverse events supports the use of this device as a valid tool to treat DED, blepharitis, and MGD. Further controlled studies and longer follow up could yield additional information.

DISCLOSURE

D. Schanzlin received compensation from NuSight Medical for participating in the study. J. Olkowski has a financial interest in NuSight Medical. The remaining authors have no funding or conflict of interest to disclose.

REFERENCES

1. Farand KF, Friman M, Stillman I, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. *Am J Ophthalmol*, 2017 Oct;182:90–98.
2. Lemp MA, et al. Distribution of aqueous deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea* 2012; 31:472–478.
3. The International Workshop on Meibomian gland Dysfunction. *Invest Ophthalm Vis Sci*. 2011; 52:1917–2085
4. Bron A, Benjamin L, Snibson GAJ. Meibomian gland disease. Classification and grading of lid changes. *Eye* 5:395 (1991)
5. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. *Invest Ophthalmol Vis Sci* 2011;52:2050–2064
6. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci* 2011;52:1930–1937

7. Gupta PK, Stevens M, Kashyap N, Priestley Cornea April 2018;37(4)426–30.
8. Wolff E. The muco-cutaneous junction of the lid margin and the distribution of the tear fluid. *Trans Ophthalmol Soc U K* 1946; 66:291–308.
9. Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. *Exp Eye Res* 2004; 78:367–70.
10. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye WorkShop 2007 *Ocul Surf* 2007;5(2):75–92.
11. Tsubota K, Yamada M. Tear evaporation from the ocular surface. *Invest Ophthalmol Vis Sci* 1992;33:2942–50.
12. Blackie CA, Korb DR. The diurnal secretory characteristics of individual meibomian glands. *Cornea* 2010;29(1):34–8.
13. Foulks G, Bron AJ Meibomian gland dysfunction: A clinical scheme for description, diagnosis, classification, and grading. *Ocul Surf* 2003 Jul;1(3):107–26.
14. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis (Review). *Cochrane Database Syst Rev* 2012;16:5.
15. Sullivan BD, Crews LA, Messmer EM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: Clinical implications. *Acta Ophthalmol* doi: 10. 16. 289.
16. Pult H, Riede-Pult BH, Nichols JJ. Relation between upper and lower lids' meibomian gland morphology, tear film, and dry eye. *Optom Vis Sci* 2012;89(3): E310–5.